A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations
Latest Information Update: 21 Sep 2024
At a glance
- Drugs Domvanalimab (Primary) ; Zimberelimab (Primary) ; Carboplatin; Cisplatin; Paclitaxel; Pembrolizumab; Pemetrexed
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms STAR-121
- Sponsors Gilead Sciences
- 15 Aug 2024 Status changed from recruiting to active, no longer recruiting.
- 08 May 2024 According to an Arcus Biosciences media release, the company is expecting to complete enrollment by the second half of 2024.
- 05 Apr 2024 Planned End Date changed from 1 Dec 2027 to 1 Sep 2027.